205 related articles for article (PubMed ID: 30121949)
1. Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.
Abeykoon JP; Zanwar S; Ansell SM; Winters J; Gertz MA; King RL; Murray D; Habermann T; Dingli D; Muchtar E; Go RS; Leung N; Inwards DJ; Buadi FK; Dispenzieri A; Lacy MQ; Lin Y; Gonsalves WI; Kourelis T; Witzig TE; Thompson C; Vincent Rajkumar S; Kyle RA; Kumar S; Kapoor P
Am J Hematol; 2018 Nov; 93(11):1384-1393. PubMed ID: 30121949
[TBL] [Abstract][Full Text] [Related]
2. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
Gustine JN; Meid K; Dubeau T; Hunter ZR; Xu L; Yang G; Ghobrial IM; Treon SP; Castillo JJ
Br J Haematol; 2017 Jun; 177(5):717-725. PubMed ID: 28485115
[TBL] [Abstract][Full Text] [Related]
3. Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Branagan A; Hunter Z; Treon SP
Arch Ophthalmol; 2006 Nov; 124(11):1601-6. PubMed ID: 17102008
[TBL] [Abstract][Full Text] [Related]
4. Waldenström macroglobulinemia.
Gertz MA
Hematology; 2012 Apr; 17 Suppl 1():S112-6. PubMed ID: 22507796
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
6. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
7. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):100-3. PubMed ID: 19362987
[TBL] [Abstract][Full Text] [Related]
8. Hyperviscosity syndrome in plasma cell dyscrasias.
Mehta J; Singhal S
Semin Thromb Hemost; 2003 Oct; 29(5):467-71. PubMed ID: 14631546
[TBL] [Abstract][Full Text] [Related]
9. Studies of the hyperviscosity syndrome. II. Macroglobulinemia.
MacKenzie MR; Babcock J
J Lab Clin Med; 1975 Feb; 85(2):227-34. PubMed ID: 803540
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of therapeutic procedure for Waldenström's macroglobulinemia with hyperviscosity syndrome.
Ito K; Kawasaki T; Hirano K; Sekiguchi N
Ther Apher Dial; 2024 Jun; 28(3):417-423. PubMed ID: 38069574
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA
Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770
[TBL] [Abstract][Full Text] [Related]
12. Clinical features of Waldenstrom macroglobulinemia in Korea.
Bang SM; Park SR; Park SH; Cho EK; Yoon SS; Shin DB; Lee JH; Park S; Kim BK; Kim NK
Korean J Intern Med; 2004 Sep; 19(3):137-40. PubMed ID: 15481603
[TBL] [Abstract][Full Text] [Related]
13. Progression in smoldering Waldenstrom macroglobulinemia: long-term results.
Kyle RA; Benson JT; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Melton LJ; Rajkumar SV
Blood; 2012 May; 119(19):4462-6. PubMed ID: 22451426
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.
Kyle RA; Therneau TM; Dispenzieri A; Kumar S; Benson JT; Larson DR; Melton LJ; Rajkumar SV
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):184-6. PubMed ID: 23490989
[TBL] [Abstract][Full Text] [Related]
15. Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia.
Menke MN; Feke GT; McMeel JW; Treon SP
Invest Ophthalmol Vis Sci; 2008 Mar; 49(3):1157-60. PubMed ID: 18326744
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic Waldenstrom's macroglobulinemia.
Alexanian R; Weber D; Delasalle K; Cabanillas F; Dimopoulos M
Semin Oncol; 2003 Apr; 30(2):206-10. PubMed ID: 12720137
[TBL] [Abstract][Full Text] [Related]
17. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia.
Mullen EC; Wang M
Clin J Oncol Nurs; 2007 Feb; 11(1):87-95. PubMed ID: 17441400
[TBL] [Abstract][Full Text] [Related]
18. Blood viscosity in Waldenström macroglobulinemia.
MacKenzie MR; Lee TK
Blood; 1977 Apr; 49(4):507-10. PubMed ID: 402961
[TBL] [Abstract][Full Text] [Related]
19. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
[No Abstract] [Full Text] [Related]
20. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2017 Feb; 92(2):209-217. PubMed ID: 28094456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
